Role of the cannabinoid CB1 receptor in methamphetamine-induced social and recognition memory impairment. 2022

Mehdi Khodamoradi, and Fatemeh Tirgar, and Hamed Ghazvini, and Raheleh Rafaiee, and Seyedeh Masoumeh Seyedhosseini Tamijani, and Narges Karimi, and Ali Yadegari, and Ali Siahposht Khachaki, and Javad Akhtari
Substance Abuse Prevention Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.

Methamphetamine (METH) has been reported to induce social and recognition memory impairment. Evidence suggests that the cannabinoid system has an important modulatory role in cognitive processing and social interaction. Nonetheless, no previous study has investigated the probable role of the cannabinoids system on METH-induced deficits of novel object recognition (NOR) memory and social interaction. Adult male rats were given a neurotoxic METH regimen (four injections of 6 mg/kg, s.c, at 2 h intervals). One week later, they were examined for either NOR or social interaction in different groups. The cannabinoid type 1 receptor (CB1R) antagonist rimonabant (1 or 3 mg/kg, i.p.) improved METH-induced impairment of the acquisition, consolidation, and retrieval, but not reconsolidation, of NOR and also METH-induced impairment of social behavior. Administration of the CB1R agonist WIN 55,212-2 (WIN; 3 or 5 mg/kg, i.p.) did not affect memory deficits or social behavior impairment induced by METH. Our findings may indicate that METH neurotoxicity impairs social and recognition memory. On the other hand, the CB1R antagonist rimonabant, but not the CB1R agonist WIN, prevented these negative effects of METH neurotoxicity. Thus, it seems that the CB1R can be targeted to prevent the adverse effects of METH on cognition and social behavior, at least at experimental levels.

UI MeSH Term Description Entries
D008297 Male Males
D008569 Memory Disorders Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions. Memory Loss,Age-Related Memory Disorders,Memory Deficits,Memory Disorder, Semantic,Memory Disorder, Spatial,Memory Disorders, Age-Related,Retention Disorders, Cognitive,Semantic Memory Disorder,Spatial Memory Disorder,Age Related Memory Disorders,Age-Related Memory Disorder,Cognitive Retention Disorder,Cognitive Retention Disorders,Deficit, Memory,Deficits, Memory,Memory Deficit,Memory Disorder,Memory Disorder, Age-Related,Memory Disorders, Age Related,Memory Disorders, Semantic,Memory Disorders, Spatial,Memory Losses,Retention Disorder, Cognitive,Semantic Memory Disorders,Spatial Memory Disorders
D008694 Methamphetamine A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed. Deoxyephedrine,Desoxyephedrine,Desoxyn,Madrine,Metamfetamine,Methamphetamine Hydrochloride,Methylamphetamine,N-Methylamphetamine,Hydrochloride, Methamphetamine,N Methylamphetamine
D002186 Cannabinoids Compounds having the cannabinoid structure. They were originally extracted from Cannabis sativa L. The most pharmacologically active constituents are TETRAHYDROCANNABINOL; CANNABINOL; and CANNABIDIOL. Cannabinoid
D000077285 Rimonabant A pyrazole and piperidine derivative that acts as a selective cannabinoid type-1 receptor (CB1 RECEPTOR) antagonist. It inhibits the proliferation and maturation of ADIPOCYTES, improves lipid and glucose metabolism, and regulates food intake and energy balance. It is used in the management of OBESITY. Acomplia,N-(Piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride,Rimonabant Hydrochloride,SR 141716,SR 141716A,SR-141716A,SR141716,SR141716A,Zimulti
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D043884 Receptor, Cannabinoid, CB1 A subclass of cannabinoid receptor found primarily on central and peripheral NEURONS where it may play a role modulating NEUROTRANSMITTER release. Cannabinoid Receptor CB1,CB1 Receptor,Receptor CB1, Cannabinoid,Receptor, CB1
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D020258 Neurotoxicity Syndromes Neurologic disorders caused by exposure to toxic substances through ingestion, injection, cutaneous application, or other method. This includes conditions caused by biologic, chemical, and pharmaceutical agents. Poisoning, Nervous System,Encephalopathy, Toxic,Nervous System Poisoning,Neurotoxic Disorders,Neurotoxin Diseases,Neurotoxin Disorders,Toxic Encephalitis,Encephalitides, Toxic,Encephalitis, Toxic,Encephalopathies, Toxic,Nervous System Poisonings,Neurotoxic Disorder,Neurotoxicity Syndrome,Neurotoxin Disease,Neurotoxin Disorder,Poisonings, Nervous System,Syndrome, Neurotoxicity,Syndromes, Neurotoxicity,Toxic Encephalitides,Toxic Encephalopathies,Toxic Encephalopathy
D063387 Cannabinoid Receptor Antagonists Compounds that inhibit or block the activity of CANNABINOID RECEPTORS. Cannabinoid Antagonist,Cannabinoid Blocker,Cannabinoid Receptor Antagonist,Cannabinoid Receptor Blocker,Cannabinoid Antagonists,Cannabinoid Blockers,Cannabinoid Receptor Blockers,Antagonist, Cannabinoid,Antagonist, Cannabinoid Receptor,Antagonists, Cannabinoid,Antagonists, Cannabinoid Receptor,Blocker, Cannabinoid,Blocker, Cannabinoid Receptor,Blockers, Cannabinoid,Blockers, Cannabinoid Receptor,Receptor Antagonist, Cannabinoid,Receptor Antagonists, Cannabinoid,Receptor Blocker, Cannabinoid,Receptor Blockers, Cannabinoid

Related Publications

Mehdi Khodamoradi, and Fatemeh Tirgar, and Hamed Ghazvini, and Raheleh Rafaiee, and Seyedeh Masoumeh Seyedhosseini Tamijani, and Narges Karimi, and Ali Yadegari, and Ali Siahposht Khachaki, and Javad Akhtari
March 2023, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih,
Mehdi Khodamoradi, and Fatemeh Tirgar, and Hamed Ghazvini, and Raheleh Rafaiee, and Seyedeh Masoumeh Seyedhosseini Tamijani, and Narges Karimi, and Ali Yadegari, and Ali Siahposht Khachaki, and Javad Akhtari
March 2020, Behavioural brain research,
Mehdi Khodamoradi, and Fatemeh Tirgar, and Hamed Ghazvini, and Raheleh Rafaiee, and Seyedeh Masoumeh Seyedhosseini Tamijani, and Narges Karimi, and Ali Yadegari, and Ali Siahposht Khachaki, and Javad Akhtari
June 2007, The European journal of neuroscience,
Mehdi Khodamoradi, and Fatemeh Tirgar, and Hamed Ghazvini, and Raheleh Rafaiee, and Seyedeh Masoumeh Seyedhosseini Tamijani, and Narges Karimi, and Ali Yadegari, and Ali Siahposht Khachaki, and Javad Akhtari
August 2016, Proceedings of the National Academy of Sciences of the United States of America,
Mehdi Khodamoradi, and Fatemeh Tirgar, and Hamed Ghazvini, and Raheleh Rafaiee, and Seyedeh Masoumeh Seyedhosseini Tamijani, and Narges Karimi, and Ali Yadegari, and Ali Siahposht Khachaki, and Javad Akhtari
June 2009, Psychopharmacology,
Mehdi Khodamoradi, and Fatemeh Tirgar, and Hamed Ghazvini, and Raheleh Rafaiee, and Seyedeh Masoumeh Seyedhosseini Tamijani, and Narges Karimi, and Ali Yadegari, and Ali Siahposht Khachaki, and Javad Akhtari
October 2023, ACS chemical neuroscience,
Mehdi Khodamoradi, and Fatemeh Tirgar, and Hamed Ghazvini, and Raheleh Rafaiee, and Seyedeh Masoumeh Seyedhosseini Tamijani, and Narges Karimi, and Ali Yadegari, and Ali Siahposht Khachaki, and Javad Akhtari
December 2004, Psychopharmacology,
Mehdi Khodamoradi, and Fatemeh Tirgar, and Hamed Ghazvini, and Raheleh Rafaiee, and Seyedeh Masoumeh Seyedhosseini Tamijani, and Narges Karimi, and Ali Yadegari, and Ali Siahposht Khachaki, and Javad Akhtari
February 2008, Psychopharmacology,
Mehdi Khodamoradi, and Fatemeh Tirgar, and Hamed Ghazvini, and Raheleh Rafaiee, and Seyedeh Masoumeh Seyedhosseini Tamijani, and Narges Karimi, and Ali Yadegari, and Ali Siahposht Khachaki, and Javad Akhtari
November 1998, Psychopharmacology,
Mehdi Khodamoradi, and Fatemeh Tirgar, and Hamed Ghazvini, and Raheleh Rafaiee, and Seyedeh Masoumeh Seyedhosseini Tamijani, and Narges Karimi, and Ali Yadegari, and Ali Siahposht Khachaki, and Javad Akhtari
August 1999, European journal of pharmacology,
Copied contents to your clipboard!